EU regulations call for the use of alternative methods to animal testing. During the last decade, an increasing number of alternative approaches have been formally adopted. In parallel, new 3Rs-relevant technologies and mechanistic approaches have increasingly contributed to hazard identification and risk assessment evolution. In this changing landscape, an EPAA meeting reviewed the challenges that different industry sectors face in the implementation of alternative methods following a science-driven approach.
, requires in vitro/in chemico testing to be conducted for endpoints such as skin corrosion and irritation, eye hazards, mutagenicity and skin sensitisation unless certain conditions apply (e.g., the test chemical falls outside of the applicability domain of the available in vitro/in chemico methods, the results obtained from such methods are not adequate for classification and risk assessment or in case of a positive result in an in vitro genotoxicity study). The EU regulation on classification, labelling and packaging of substances and mixtures (EU CLP; EC, 2008 , ECEU, 2016b , which implemented the UN Globally Harmonised System (UN GHS) for classification and labelling of substances and mixtures in the European Union, encourages the use of tiered weight-of-evidence evaluations, including the use of information from in vitro testing. Similarly, the EC regulation 528/2012 concerning biocidal products (EC, 2012) and the EC regulation 1107/ 2009 concerning plant protection products (EC, 2009b) request that animal testing is conducted as a last resort when no other methods are available, and encourage the use of testing strategies and of non-animal alternative approaches. Also in the area of pharmaceuticals, the European Medicines Agency (EMA) provides an overview of opportunities for implementation of the 3Rs (replacement, reduction and refinement) in the current regulatory testing requirements for medical products for human use and report on the actions taken to review and update EMA guidelines to implement best practice with regard to 3Rs in regulatory testing of medicinal products (EMA, 2016a (EMA, , 2016b . Finally, the EU Directive on the protection of animals used for scientific purposes (EC, 2010a) states in article 13 (1) that "Member States shall ensure that a procedure is not carried out if another method or testing strategy for obtaining the result sought, not entailing the use of a live animal, is recognized under the legislation of the Union".
More recently, the mode of action concept, the Tox21 strategy, the concept of pathways of toxicity and the adverse outcome pathway (AOP) framework aim at toxicity testing and assessment based on indepth understanding of the in vivo physiological and toxicological processes in humans and on their relation to specific toxicological endpoints (Ankley et al., 2010; OECD, 2012a; OECD, 2017a; US-EPA, 2015; US NRC, 2007) . New technologies and paradigms are gradually transforming these concepts into applicable animal-free toxicity testing systems by e.g., implementation of libraries of generic profiles of genes (genomics), proteins (proteomics) and metabolites (metabonomics) describing molecular initiators, pathways and key events of toxicity within tissues, organisms and biological systems (Berg et al., 2011) .
In view of such regulatory and scientific framework, the European Partnership for Alternative Approaches to Animal Testing (EPAA) organized a meeting on 29 April 2016 in Brussels, Belgium to address the current state of play of non-animal approaches for toxicity assessment. EPAA represents a private-public voluntary initiative between the European Commission, European trade associations and companies from eight industry sectors committed to pooling knowledge and resources with the aim to replace, reduce and refine (3Rs) animal use in regulatory testing. The meeting from April 2016 aimed in particular to review the status of implementation of alternative methods in light of the current scientific opportunities and identify the challenges different industry sectors may face.
The meeting comprised representatives from different industry sectors including agrochemicals, chemicals, cosmetics, detergents, fragrances, pharmaceuticals, veterinary immunological and pharmaceutical products. Furthermore representatives from different Directorate Generals of the European Commission attended the meeting including Environment, Growth, Health, Joint Research Centre, Research & Innovation. The meeting addressed i) the current scientific and technological progress and limitations of alternative approaches in the different areas and endpoints of toxicity, ii) the areas where alternative methods have been successfully used for regulatory purposes and areas proving to be more challenging, iii) the current scientific and technical challenges to be overcome in order to broaden the regulatory use of alternatives. These three concepts were considered as a basis for discussions during the meeting.
Even though the regulatory requirements and the technical applications of 3Rs may differ between sectors, the science forming the basis for 3Rs application is common across industry sectors and each of these faces similar scientific challenges. Therefore during the meeting, case studies that were non sector-specific, were addressed for the different toxicological areas although it is recognized that risk assessment versus risk management can substantially differ between sectors. The following chapters provide an overview of the toxicological endpoints and case studies addressed, with a focus on the current status and main challenges encountered in the different areas and endpoints of toxicity.
Skin irritation and corrosion & eye irritation and serious damage
The current European Union regulatory framework as described above, promotes the reduction of animals used for regulatory testing purposes, whilst enabling informed decisions and maintaining a high level of protection of European citizens. This is of high importance in both occupational and consumer environments in order to provide the right information to workers and consumers. Indeed, such European regulatory framework applies not only to substances but also to mixtures encompassing different consumer good products including detergents and cleaning products (CLP (EC) Regulation No 1272 EC, 2008) .
In the area of skin irritation and corrosion, replacement alternatives have been validated and adopted in the regulation as early as 2000 in the European Union and in 2004 at the OECD level. Current internationally agreed approaches recommend the use of an Integrated Approach for Testing and Assessment (IATA) adopted as OECD Guidance Document 203 (OECD, 2014a) . The IATA allows to replace or minimize, to the extent possible, the use of in vivo animal testing whilst ensuring human safety (OECD, 2014a) . It comprises in a sequential way: i) the use of existing information, physico-chemical properties and non-testing methods; ii) a weight-of-evidence evaluation of the existing data and iii) if needed, the conduct of prospective testing. Although no single in vitro test method can cover the full range of skin corrosion and irritation responses observed in the traditional in vivo Draize rabbit test, the currently validated and adopted in vitro methods for skin irritation and corrosion can replace the in vivo test when combined within tiered testing strategies for predicting the potential skin irritation and corrosion hazard of a test chemical (OECD, 2014a; Eskes and Hoffmann, 2017a) .
In Europe, where the UN GHS Cat. 3 is not implemented, the regulatory adopted in vitro test methods for predicting skin irritation, may be used to distinguish non-classified from classified test chemicals (OECD, 2014a; 2015a) . Furthermore, the adopted test methods for predicting skin corrosion can be used to reliably distinguish skin corrosives from non-corrosives and to subcategorize the corrosive subcategories when their limitations and domain of application are adequately considered (ECHA, 2017; Eskes and Hoffmann, 2017b) . Finally, when combined together, the adopted test methods for skin irritation and for skin corrosion provide sufficient information for the decision on the potential of the substance or mixture to cause skin irritation. Animal testing should therefore be used only as a last resort when e.g., discrimination between optional corrosive sub-categories 1B and 1C for chemicals outside of the applicability domain of OECD TG 435 is required, or the test chemical cannot be tested with the in vitro test methods currently adopted by the OECD due to limitations or non-applicability. However, the harmonised regulatory implementation of the current internationally agreed Guidance Document on such test strategies to identify skin corrosives (including sub-categories), skin irritants as well test chemicals that do not require classification for skin irritation is critical to ensure that the animal testing is no longer conducted for such an endpoint.
In the area of eye irritation and serious damage, a number of in vitro test methods have been regulatory accepted for the identification of substances and mixtures that i) require classification for serious eye damage (EU CLP/UN GHS Category 1) and ii) do not require classification for eye hazard effects (EU CLP/UN GHS No Category) (ECHA, 2017) . However, there is currently no in vitro test method accepted for the identification of eye irritation (EU CLP/UN GHS Category 2). Furthermore, although these assays may be combined in sequential testing strategies and/or within IATA as recently adopted within the OECD GD 263 (Scott et al., 2010; OECD GD 263, 2017b) , such strategies do not currently allow for the full replacement of the rabbit test on acute serious eye damage and eye irritation (ECHA, 2017) . One possible reason is that the in vitro test methods currently accepted to identify serious eye damage (EU CLP/UN GHS Category 1) may not cover all mechanisms of action resulting in serious eye damage, including, in particular, the persistence of effects as observed in vivo at day 21 in the rabbit eye test method. This situation might lead to circumstances where an in vivo test method may need to be used as a last resort, in particular since persistence of tissue effects has been shown to be an important driver for the in vivo classification of serious eye damage (EU CLP/UN GHS Category 1) (Adriaens et al., 2014; Barroso et al., 2017 ). An alternative methodology for mixtures could be the use of the additivity approach as required in case of absence of test data (CLP Regulation (EC) No 1272 EC, 2008) . However for detergents and cleaning products, such an approach has been found to systemically over-predict non-Category 1 detergents as EU CLP/UN GHS Category 1. As a consequence, besides not meeting the current requirements for a scientifically valid approach, the resulting over-labelling could potentially confuse end-users and lead to the underestimation of the real risk of a mixture when this is merited due to trivialization of labelling (Cazelle et al., 2014) . For the reasons mentioned above, the International Association for Soaps, Detergents and Maintenance Products (A.I.S.E.) undertook since 2010 a multi-year program to investigate the usefulness of regulatory accepted in vitro test methods to reliably classify detergent and cleaning products without the use of animals. In particular, the inclusion of histopathology as an additional endpoint to the Isolated Chicken Eye (ICE) test, an organotypic accepted test method (OECD, 2013a; EC, 2010b) , was found to increase the sensitivity in predicting potential serious eye damage hazard (EU CLP/UN GHS Category 1) for non-extreme pH detergent and cleaning products (Cazelle et al., 2014) . Interestingly, it was demonstrated that histopathology improves especially the identification of serious eye damage effects resulting from persistence of effects in the in vivo rabbit test method (Cazelle et al., 2014) .
Combination of the standard ICE with histopathology can therefore be used as part of a Weight of Evidence (WoE) assessment, together with other information, to identify the potential eye hazard of nonextreme pH detergent and cleaning products, including the identification of eye irritation hazard effects (EU CLP/UN GHS Cat. 2) (OECD, 2017b). However, harmonised approaches for the regulatory acceptance of such WoE assessments still remains a challenge within Europe. In order to make best use of enhanced test methods (as compared to the existing approaches) and to ultimately replace the use of animals for the testing of mixtures such as detergents and cleaning products, the harmonised acceptance of such WoE assessments will be critical.
Skin sensitisation
In the area of skin sensitisation, an Adverse Outcome Pathway has been defined (OECD, 2012b ) and a number of animal-free test methods addressing specific key events and/or mechanisms of action have been developed, validated and gained regulatory acceptance during the last decade (OECD, 2015b (OECD, , 2015c 2017c) . Human data, when available, and the LLNA as the only animal-based test that underwent formal validation (OECD TG 429, 2010), became the gold standard used for the development and validation of animal-free test methods for skin sensitisation (Basketter et al., 2014) . While the LLNA covers the development of a skin sensitisation reaction up to the organ level, the available animal-free methods each focus on one or several, but not all key events along the adverse outcome pathway (OECD, 2012b) .
With the 7th Amendment of the EU Cosmetics Directive 76/768/ EWG, a marketing ban has been implemented for cosmetic products which contain ingredients tested in animals after March 2009 (acute endpoints) or March 2013 (repeated dose and systemic toxicity endpoints) (EC, 2009a) . Furthermore, following the amendment of the REACH regulation in 2016, a combination of in vitro/in chemico studies is required to be conducted as first option before testing in vivo as a last resort to assess the skin sensitisation hazard of a chemical (EC, 2016b) .
The question how to combine the results of different animal-free methods to reach a conclusion on the overall skin sensitising properties of a compound in the context of the AOP was subject of an EPAA workshop with regulators and industry in 2015 (Basketter et al., 2015) as well as of an adopted OECD guidance document (OECD, 2016a) . In addition, a number of Defined Approaches (DAs) to testing and assessment as well as an Integrated Approach to Testing and Assessment (IATA) have been proposed for the purpose of skin sensitisation hazard assessment, potency categorization and risk assessment (OECD, 2016b; OECD, 2016b) . In particular, a Defined Approach to testing and assessment consists of a fixed data interpretation procedure used to interpret data generated with a defined set of information sources (e.g. in silico, in chemico, in vitro and other relevant information such as physico-chemical properties), that can either be used on its own, or together with other information sources within an IATA, to satisfy a specific regulatory need. Several examples of Defined Approaches developed for skin sensitisation hazard assessment and/or potency categorization can be found within the OECD, 2016c.
Here, an overview is given of the toolbox currently available that may be used in combination in e.g. DAs and/or IATAs to address the different mechanistic events relevant to the skin sensitisation adverse outcome pathway.
3.1. Bioavailability, i.e., the capability of a test chemical to reach viable cell layers Useful in vitro and in silico methods for assessing skin absorption and systemic availability of chemicals are available (OECD, 2004; Basketter et al., 2007; Smith and Hotchkiss, 2001) , which, however, require appropriate implementation. Furthermore, there is a need for additional methods that allow assessment of compound disposition, metabolism and kinetics in the skin, to obtain e.g., information on kinetics, potential tissue bioaccumulation and actual exposure at cellular level (Pendlington et al., 2008) .
3.2. Haptenation, i.e., the covalent reaction of a test chemical with a 'Carrier protein' Sensitising chemicals are generally reactive, electrophilic chemicals that form covalent bonds with nucleophilic nuclei on proteins (haptens), although some chemicals require activation by host enzymes (pro-haptens) or by oxidization (pre-haptens) to acquire sufficient electrophilicity. Occasionally, non-electrophilic binding occurs through disulphide exchange or co-ordination bonds (Chipinda et al., 2011) . The reaction rate and mechanism by which the chemical reacts with the nucleophilic groups on the protein influence its allergenic potency (Albrekt et al., 2014; Aleksic et al., 2009; Chipinda et al., 2010) .
Tools for the animal-free assessment of haptenation are well established and have been extensively described such as the Direct Peptide Reactivity Assay (DPRA) falling within the OECD TG 442C (OECD, 2015b) and the Peroxidase Peptide Reactivity Assay (PPRA) which includes the metabolic activation (Gerberick, 2016; Gerberick et al., 2008 Gerberick et al., , 2009 Lalko et al., 2012) . In vitro studies suggest that the specificity of the covalent modification is time and dose dependent and that the target proteins in vitro become more general and less discriminative over time and with increasing concentrations of the chemical (Manchanda et al., 2002) . A better understanding is required of the features (if any) that make the hapten-protein complex a sensitiser, determine its potency and drive T helper cell type 1 (Th1)-Th2 skewing.
3.3. Inflammation, i.e., innate recognition followed by activation of the innate immunity
There is increasing evidence underpinning the central role of innate immune responses and inflammation in skin sensitisation (Corsini et al., 2013a (Corsini et al., , 2013b Ray et al., 2012; Esser et al., 2012; Martin et al., 2008; Antonopoulos et al., 2008) . The acquired knowledge has resulted in several assays performed with human primary keratinocytes (KCs) or KC cell lines either as a submerged culture or as reconstructed human epidermis (RhE), some of which have been adopted at the OECD level such as the ARE-Nrf2 Luciferase test methods falling within the OECD TG 442D (OECD, 2015c) .
Additional advanced test methods also exist that assess chemical reactivity, oxidative stress and inflammation by measuring IL-18 levels or chemical sensitisation using a specific gene signature (Corsini et al., 2013a; Gibbs et al., 2013; Galbiati et al., 2017) . Furthermore, there is growing evidence that some mechanisms well established for skin sensitisation (i.e., TLR2, TLR4 and ROS signalling, and NLRP3 inflammasome assembly) also play a role in lung sensitisation (Roggen, 2014) . A better understanding is required about the subtle balance between danger signals or intracellular interactions promoting distinct immune phenotypes. Furthermore, it is imperative to understand how reactivity rate and mechanisms of haptenation affect this balance.
Dendritic cell activation, i.e., from innate responses to dendritic cell (DC) maturation
It is generally accepted that activation of DCs results in prominent phenotypic and functional changes including enhanced levels of MHC class I and co-stimulatory molecules (e.g. cluster of differentiation (CD54, CD80 and CD86) and receptors that are essential for cell migration) and antigen-presenting capacity (Tan and O'Neil, 2005) . Extensive genomic analysis of monocyte-derived dendritic cells (Mo-DCs), a human monocytic leukaemia cell line (THP-1) and an acute myeloid leukaemia cell line (MUTZ-3) exposed to skin sensitisers exerting cysteine and cysteine/lysine reactivity has identified genes describing the primary pathways of skin sensitisation, i.e. signalling through transcription factors Nrf2 and aryl hydrocarbon receptor (AHR), and protein ubiquitination (Migdal et al., 2013; Johansson et al., 2011) . Lysinereactive chemicals appeared to be less efficient (Johansson et al., 2011) . By stratifying the sensitising chemicals into chemical reactivity groups, a number of canonical pathways known to be involved in the biology of sensitisation were confirmed, while novel pathways were identified. Sensitisers with different reactivity mechanisms or potency were further shown to engage different pathways, indicating that the biological endpoint of T-cell priming is achieved through different upstream mechanisms (Albrekt et al., 2014) .
The available tools for assessing DC activation and maturation can be grouped based on the readout for sensitisation, i.e. phenotypic changes, changes in gene expression, and changes in protein expression. A number of methods have been adopted for the purpose of this key event of the skin sensitisation AOP as described within the OECD TG 442E including the human cell line activation test (h-CLAT), the U937 cell line activation test (U-SENS™ and the Interleukin-8 Reported gene assay (IL-8 Luc assay) (OECD, 2017c) . A better understanding of how the early gene changes contribute (or not) to the expression of maturation markers may help to understand and resolve the reasons behind the low specificity of the available test methods. Furthermore, understanding better the association between pathway activity and chemical class will help the development of assays for subcategorization.
3.5. Dendritic cell migration, i.e., translating the message into specific actions
The molecular mechanisms driving migration of DC to and from peripheral tissues have been reviewed (Villablanca et al., 2008) . The acquired knowledge has resulted in a DC migration assay proposed to assess the ratio between cell migration towards CXCL12 or to CCL5 based on the fact that sensitiser-induced migration depends on CXCL12 whereas irritant-induced cell migration is CCL5 dependent (Rees et al., 2011) . While the preliminary data were promising (no misclassification), further evaluation studies performed with more chemicals are required. The test is also expensive and rather complicated which may hamper its application by industry. More work is therefore required to refine the test to make it more attractive for industrial use. In order to mimic the in vivo situation more closely, human MUTZ-3 derived Langerhans cells have been incorporated in a 3D human skin equivalent (Kosten et al., 2015) . The migration behaviour of the MUTZ-3 cells after contact with a sensitiser or an irritant, respectively, is similar to that in the cellular assay, but the test system is still waiting for validation.
T-cell priming and proliferation: the turning point
Primary T-cell responses in lymph nodes require contact-dependent information exchange between T cells and DCs (Jelley- Gibbs et al., 2008; Kimber et al., 2012; Mempel et al., 2004; Xu et al., 1996) . Th17 cells were shown to play a crucial role in allergen-specific cellular and humoral immune responses through the activation of both contact hypersensitivity and airway hyperresponsiveness. The human T-cell priming assay (hTCPA) is based on a co-culture system that measures the effect derived from the contact of freshly isolated T cells with autologous DC cells previously activated and chemically modified by the test substance. The activated cells can be co-cultured with autologous skin. T-cell proliferation and interferon-γ secretion are measured in separate assays, while the skin explants are analysed histologically.
Knowledge on the T-cell populations that are activated by xenobiotics is increasing. It is, however, not clear yet how Th1-Th2 skewing and the balance between regulatory and effector T-cells is controlled. Tcell stimulation is a pivotal event, being part of the induction phase as well as the elicitation phase of skin sensitisation. Potency assessment performed with T-cell-based assays needs therefore to build on an indepth understanding of mechanisms behind potency of sensitisation induction on the one hand and severity of clinical symptoms on the other hand. Furthermore, while co-culturing the activated cells with autologous skin provides information about the clinical relevance of the chemical-specific T cells, no information is acquired with respect to skin penetration, bioavailability and early inflammatory responses leading to sensitisation.
Conclusions
With the available toolbox, including the OECD approved test methods, that provide partial information on whether or not a substance is likely to induce skin sensitisation, the overall status of nonanimal test methods to assess skin sensitisation can be regarded as advanced (Reisinger et al., 2015) . Nonetheless, developmental efforts are still required to provide a better scientific understanding of the reactions involved in each of the key events as described above, and help to further close the gaps along the adverse outcome pathway. Furthermore, technological limitations need to be overcome to allow the use of animal-free methods also for e.g. highly lipophilic molecules, surfactants and mixtures. Finally, although these methods allow to predict the hazard of a substance (skin sensitiser: yes/no) there is a need for assessing the potency of the tested materials in order to allow for a complete regulatory safety assessment and GHS subcategorization. However, although the combinations of individual test methods within DAs have been proposed to predict both hazard and potency, potency assessment is currently not yet possible for regulatory purposes based solely on animal-free methods.
Genotoxicity
The assessment of genotoxicity represents an essential component of the safety assessment of all types of substances. Numerous OECD-validated in vitro methods are available to evaluate genotoxicity in somatic cells, and many of them have practical relevance in regulatory safety assessment (Table 1) . Not all of these methods address the same adverse event, as genotoxicity can manifest in different types of damage. While some test methods are suited to detect gene mutations in bacteria or mammalian cells, others were optimized to identify chromosomal damage. In order to investigate the genotoxic hazard of an unknown compound, all three types of DNA damage need to be addressed, i.e., gene mutation as well as structural and numerical chromosomal damage. As no single in vitro or in vivo test can display all types of lesions, a battery of tests needs to be applied. This results in a tiered approach for genotoxicity testing, starting with a combination of several in vitro methods. In case of conflicting results, a suited in vitro or in vivo followup study needs to be chosen, in accordance with the relevant legal framework (e.g., animal testing is prohibited for cosmetic products and ingredients in Europe (Regulation No 1223 , EC, 2009a .
A decade ago, it was shown that with the number of in vitro genotoxicity tests combined, the chance to obtain 'misleading' positive results rises (Kirkland et al., 2005) . Several actions have been undertaken or are still underway to overcome this challenge, striving for a scientifically robust genotoxicity assessment that avoids in vivo follow-up tests Kirkland et al., 2007) . These include the improvement of existing tests, the development of novel tests, the establishment and exploration of approaches to optimise in vitro testing accuracy, the development of databases and reference chemical lists .
During the past decade, different working groups optimized the in vitro protocols with the aim to improve their predictive capacity. One example is the in vitro micronucleus test, where the outcome of the optimisation process (Fowler et al., 2012a (Fowler et al., , 2012b (Fowler et al., , 2014 was used to adapt the corresponding OECD Testing Guideline No. 487 (2016f). Furthermore, the European Scientific Committees (EFSA, 2011; SCCS, 2016) introduced a tiered testing strategy starting with two assays (bacterial reverse mutation assay (OECD, 1997) and the in vitro micronucleus test (OECD, 2016f) instead of three to increase the test battery's predictive capacity.
Besides improvement of existing in vitro genotoxicity tests and refinement of the testing strategy, another approach aimed at the development of new in vitro test systems to overcome the limitations of cell lines. In this context, Cosmetics Europe implemented a research program The Hen's egg test for micronucleus induction (HET-MN) complements the toolbox of assays which are intended to follow up on initial positive findings, with a test system which mirrors the systemic availability of a test compound (Greywe et al., 2012) . Results obtained with the 3D Skin COMET Assay have already been used successfully to support the safety assessment of a cosmetic ingredient (Reisinger et al., 2016) .
Acute toxicity
As described above, the use of animals has been prohibited in the EU for the testing of cosmetic ingredients and finished products including acute toxicity testing (EC, 2009a) , although it may still be required in other regions in the world. Moreover in preclinical drug development, acute toxicity studies are no longer mandatory to support first clinical trials in human, as the information can be obtained from other non-lethal tests (1st range finding in vivo studies) that are carried out as part of the drug development process Chapman et al., 2010; ICH M3(R2), 2009 ). Nevertheless the regulatory requirements vary greatly across regulatory authorities in different global regions and even within regions (e.g. among the U.S. regulatory agencies) so that international harmonisation would greatly benefit from the adoption of non-animal alternatives.
Substantial progress has been made in reducing and refining animal use in the field of acute toxicity testing. In 2002, the acute oral toxicity test guideline (TG 401) was deleted in favour of versions designed to use fewer animals including the OECD TG 420, 423, and 425, (OECD, 2002a; OECD, 2002b; OECD, 2008) . Moreover, for acute inhalation toxicity, a revised version of the original test guideline (TG 403) that uses less animals and includes two study protocols, the traditional LC 50 study and a concentration versus time approach protocol (OECD, 2009a), became available. Two reduction and refinement alternatives, OECD TG 436 and TG 433 (OECD, 2009b; OECD, 2017d) were also adopted. The selection among these three test guidelines is driven by regulatory needs. To avoid unnecessary testing, the revised test guideline for acute dermal toxicity testing (OECD TG 402) should be used only if waiving is not scientifically justified (OECD, 2017e; OECD, 2016j) . Furthermore, the design of this revised TG has been optimized and aligned with the 3Rs principles by incorporating a stepwise procedure, adapted from the toxic class method, and the fixed dose procedure from the TG 420. Regulatory agencies have also adapted their policies to reduce animal use for acute toxicity assessment. The EPA has published a draft policy to waive all acute lethality dermal studies for formulated pesticide products, based on retrospective analysis of data from ca. 600 agrochemical formulations, and on the basis of which they expect will save 2500 or more laboratory animals every year (US EPA, 2016) . Also the OECD published a guidance document on considerations for waiving or bridging of mammalian acute toxicity tests applicable to pesticides and other substances (OECD, 2016j) .
Besides reduction and refinement, substantial collaborative efforts have been directed at the replacement of animal studies by alternative methods (Hamm et al., 2017) . Research on alternatives has centred on the use of in vitro cytotoxicity assays, quantitative structure-activity relationships (QSARs) approaches and the incorporation of biokinetics and metabolism data (Prieto et al., 2013) . For drug development, basal in vitro cytotoxicity methods are currently used for screening purposes together with complementary and more mechanism-based methods (e.g. cellular imaging) to better understand the origins of the cytotoxicity potential. Due to the complexity of the multiple mechanisms associated with acute systemic toxicity full replacement will require the integration of data from multiple assays/approaches with other relevant information (e.g. physicochemical information, ADME and pharmacokinetics, mechanistic information, and in vitro and in silico methods) into Integrated Approaches to Testing and Assessment (IATA) (EURL ECVAM, 2014). The development of such IATA is challenging because of the limited mechanistic understanding of the numerous Adverse Outcome Pathways (AOPs) and modes-of-actions underlying systemic toxicity. There are several projects that aim to enhance the mechanistic understanding of AOPs and provide innovative methodologies for systemic toxicity testing, such as the EU FP7 SEURAT-1 project (Gocht et al., 2015) , its H2020 successor Eu-ToxRisk (Daneshian et al., 2016) , the Tox21 programme (Attene-Ramos et al., 2013) and the ToxCast programme (Judson et al., 2010) . It is expected that eventually mode of action and associated AOPs will provide a framework for the organization and integration of non-animal data and other relevant information to predict systemic toxicity for decision making. In Europe, the Scientific Committee on Consumer Safety (SCCS) which provides opinions on health and safety risks of cosmetic products and their ingredients, reports in their notes of Guidance, 9th revision (SCCS/1564/15; SCCS, 2016) that "there are presently no validated (animal-free) replacement methods for acute and repeated dose toxicity, including reproductive and developmental toxicity, and carcinogenicity. There are also no relevant proposals currently ready in these areas for pre-validation/validation." Nevertheless the SCCS may accept, on a case-by-case basis, methods that are scientifically valid, but have not necessarily gone through the complete validation process. It is important however that they have a sufficient amount of experimental data proving their relevance and reliability including positive and negative controls (SCCS, 2016) . Furthermore, it states that for acute toxicity a "weight of evidence approach may be sufficient -such as justified conclusions from chemical grouping/read-across, (Q)SAR, in vitro studies, or repeated dose toxicity studies."
Repeated dose toxicity
The development of non-animal test methods to assess sub-acute and sub-chronic toxicity represents a long-term goal, as there are still a number of limitations to overcome. Although in vitro test systems are advancing rapidly, they are not able yet to mimic all the possible interactions, which may occur in vivo. Moreover they may not account for the complex kinetics and biotransformation processes. Another key difficulty is the derivation of safety values from in vitro data e.g. a No Observed Adverse Effect Level (NOAEL), which are traditionally used as the starting point for risk assessment (Prieto et al., 2006) . Thus a new approach is required that is able to cover the toxicity mechanisms of sub-acute and sub-chronic toxicity, their interplay, taking account of kinetics and from which the outcomes can be translated into a safe human dose.
At present non-animal test methods are mainly directed to assess effects in specific target organs. However, for systemic toxicity integrated approaches based on mode of actions/adverse outcome pathways coverage of multiple organs and systems are required. Therefore research programs have focused on the integration of in vitro, in silico and -omics technologies to understand the interactions between different tissues and systems (Basketter et al., 2012) . The SEURAT-1 project aimed to investigate toxicological modes-of-action of mainly liver toxicity, using these to develop integrated testing strategies and applying the obtained knowledge in the context of safety assessment (Gocht et al., 2015) . The mission of the EU-ToxRisk project is to further develop a quantitative aspect of this concept, covering a liver, lung, kidney and nervous system as potential target organs and integrating relevant in vitro and in silico technologies, applying this for the assessment of repeated dose systemic toxicity and developmental and reproductive toxicity (Daneshian et al., 2016) . The Cosmetics Europe Long Range Science Strategy aims to advance new approaches to safety assessment in the area of systemic toxicity through a case study driven approach, testing applicability of tools for both toxicodynamics and toxicokinetics in an integrated approach and focussed at different levels; i) determination of low or negligible exposure, ii) grouping and read-across and iii) ab initio approaches. Although these projects are widely recognized for the advances they bring, it remains a massive task to advance the science, apply the research towards practical application and obtain regulatory acceptance.
Regarding quantitative risk assessment, improved scientific knowledge on exposure, toxicokinetics, dose response and mechanisms of toxicity are essential. In some cases, testing is not considered necessary based on low exposure levels or on the Threshold of toxicological concern (TTC) concept. TTC is a widely applied risk assessment approach that establishes a human exposure threshold value for chemicals, below which there is a low probability of an appreciable risk to human health (Hartung) .
The use of read-across based on toxicity data available for suitably similar chemistry also has potential to reduce or replace animal testing. A number of case studies designed to advance the acceptance of readacross predictions for repeat-dose toxicity have been evaluated to assess the knowledge and insight they provide (Schultz and Cronin, 2017) . These case studies examined the sources of uncertainty associated with read-across. The outcomes showed that uncertainty is not only related to the quality and quantity of the read-across endpoint data, but also other factors, especially related to the justification of similarity and quality of data for the source chemicals. The investigation demonstrated that similarity in chemistry is often not enough to justify a readacross prediction and for chronic health endpoints, toxicokinetic and/or toxicodynamic similarity is essential. Data from high throughput screening, -omics, in vitro/in chemico assays and in silico tools, may provide critical information to strengthen the toxicodynamic similarity rationale but the ultimate goal is to perform case studies that integrate exposure, physiologically-based kinetic (PBPK) modelling, in silico, in vitro data, biokinetics, QIVIVE and read-across into a single workflow for the human safety assessment of a chemical. Models are needed for this purpose which correctly estimate the impact of the distribution over time, the repeated external exposure and resulting internal dose. Such models are also needed for the quantitative in vitro to in vivo extrapolation (QIVIVE) and for understanding of dose responses, so that the in vitro data can be applied for quantitative risk assessment (Blaauboer and Andersen, 2007; Yoon et al., 2015) .
Arguably the greatest challenge in the absence of animal test data for a given chemical (or related chemicals) is to predict adverse effects or lack thereof. Exploratory efforts towards an ab initio approach, linking molecular and cellular effects to higher order adverse outcomes and pharmacokinetic models, were made in SEURAT-1. The piperonyl butoxide (PBO) example (Berggren et al., 2017) demonstrated the feasibility in informing mode of action and subsequent targeted testing with in silico and in vitro approaches but stopped short of deriving a point of departure for a quantitative human risk assessment. Within the ab initio approach of the Cosmetics Europe Long Range Science Strategy the implementation of an in vitro safety pharmacology screen that covers a broad range of targets including receptors, ion channels, transporters, enzymes etc may help to avoid any undesirable pharmacological properties of cosmetic ingredients. In addition, this could serve to increase the knowledge on the mode of action.
In Europe, as for acute toxicity, the SCCS states that "for repeateddose toxicity testing, currently no validated or generally accepted alternative method is available for replacing animal testing" (SCCS, 2016). The SCCS may accept nevertheless, on a case-by-case basis, methods that are scientifically valid, but have not necessarily gone through the complete validation process, if they have a sufficient amount of experimental data proving their relevance and reliability including positive and negative controls (SCCS, 2016) . It also states that "in case no repeated-dose toxicity data or a weight of evidence approach exist, the use of animal experiments to study potential toxic effects remains at present a scientific necessity" (SCCS, 2016).
Reproductive developmental toxicity
Developmental and Reproductive Toxicity (DART) assessment encompasses the evaluation of the toxicity in reproductive ability or development of offspring after repeat administration, resulting from kinetic and/or dynamic behaviour of a chemical often associated with narrow windows of time. It requires large numbers of animals as parental and offspring generations are involved, and depending on circumstances, developmental toxicity studies can be required to be executed in two species (rodent and non-rodent). During the last years, significant changes in the DART guidelines have been or are being implemented focused on reduction and refinement (Beekhuijzen, 2017) . For pharmaceuticals, the ICH S5 guideline is being updated to potentially reduce animal use (ICH, 2015) . Regarding the use of the second species in embryo-foetal developmental studies, a tiered approach was proposed with the second species testing only conducted based on the outcome of the first species study (Hurtt et al., 2003) . The added value of the second species is also under discussion for industrial chemicals and agrochemicals. The use of blood capillary microsampling and jugular vein blood sampling for toxicokinetics in juvenile toxicity studies has the potential to reduce the animal numbers required per study (Powles-Glover et al., 2014; Beekhuijzen, 2017; Chapman et al., 2014) . For industrial chemicals, the extended one-generation reproductive toxicity study (EOGRTS) is now the information requirement for reproductive toxicity under the EU chemicals legislation (OECD, 2012c) instead of the two-generation study (OECD, 2001) for substances manufactured or imported to the EU in quantity > 100 t/y (EC, 2015). The EOGRTS offers important improvements in animal welfare through reduction and refinement in a modular study design with possible investigations of developmental neurotoxicity and/or immunotoxicity (Beekhuijzen et al., 2016) . Moreover for agrochemicals, the Commission regulation No. 283/2013 states that the EOGRTS may be considered as an alternative approach to the multi-generation study (EC, 2013) . Expected future developments include the addition of toxicokinetic assessment for industrial chemicals, the refined selection of high dose level, and the shift from standard animal studies towards tailor-made approaches using in vitro and in silico methods.
A variety of non-animal test methods have been developed and evaluated including rodent embryonic cell, tissue and whole embryo culture approaches to detect potential teratogenicity, as well as a number of non-mammalian models (e.g., zebrafish) (Brannen et al., 2016) . Although these methods have not yet been accepted for regulatory purposes, their use for pharmaceuticals and applicability for industrial chemicals is well established (Zhang et al., 2016) . The "ReProTect" project developed an in silico and in vitro test battery with potential for use in screening and Weight of Evidence assessment of reproductive toxicity. The projects' ring trial assessed 10 blinded chemicals tested in a battery of 14 in vitro assays and showed, together with a weight-of-evidence approach, a robust prediction of adverse effects on fertility and embryonic development as compared to the whole animal data (Schenk et al., 2010) . Emerging models include human embryonic stem cell (hESC) assays (Palmer et al., 2013; Kugler et al., 2017) , which appear promising to facilitate translation from predictive assays to the clinic, but still more characterization is required to understand their true potential. Challenging aspects include the limited number of compounds with adequate human data and the possible contradictions between hESC assay and preclinical animal data.
The US EPA is leading in the field of endocrine disruption (ED) by utilizing high-throughput assays and computational models. The EPA Endocrine Disruption Screening Program (EDSP) is using the high throughput data from the ToxCast program (Dix et al., 2007) to rank and prioritise chemicals based on their potential oestrogen receptor bioactivity, serving as an alternative for some of the existing EDSP Tier 1 in vitro and in vivo assays (Browne et al., 2015) .
Thus a lot of improvements have been made regarding the refinement and reduction of animal used for regulatory DART testing. However the greatest revolution will be the transition from standard animal experiments towards an Integrated Approach for Testing and Assessment (IATA) that combines information from computational, molecular and in vitro methods. IATA frameworks are increasingly used for simple toxicity endpoints and the challenge will be to develop them further for more complex endpoints like DART.
In Europe, as for acute and repeated dose toxicity, the SCCS states "for reproductive toxicity testing, currently no validated or generally accepted alternative method is available for replacing animal testing" (SCCS, 2016). The SCCS may accept nevertheless, on a case-by-case basis, methods that are scientifically valid, but have not necessarily gone through the complete validation process, if they have a sufficient amount of experimental data proving their relevance and reliability including positive and negative controls (SCCS, 2016) . It also states that "in case no reproductive toxicity data or a weight of evidence approach exist, the use of animal experiments to study potential toxic effects remains at present a scientific necessity" (SCCS, 2016).
Carcinogenicity
Carcinogenesis represents a multi-step process from the transition of normal cells into cancer cells via a sequence of stages and complex biological interactions, strongly influenced by factors such as genetics, age, diet, environment, hormonal balance or others (EURL ECVAM, 2013). Since the induction of cancer involves genetic alterations which can be induced directly or indirectly, carcinogens have conventionally been divided into two categories according to their presumed mode of action: genotoxic carcinogens and non-genotoxic carcinogens. Genotoxic carcinogens have the ability to interact with DNA and/or the cellular apparatus and thereby affect the integrity of the genome, whereas non-genotoxic carcinogens exert their carcinogenic effects through other mechanisms that do not involve direct alterations in DNA (EURL ECVAM, 2013) .
Carcinogenicity is generally assessed based on a combination of genotoxicity study package (see separate section above), and a two-year carcinogenicity study in rats and mice (OECD TG 451 and/or 453; OECD, 2009c OECD, , 2009d . The validity of the two-year carcinogenicity study has been nevertheless questioned due to the uncertainty associated with the extrapolation of data from rodents to humans, the fact that these studies are extremely time and resource-consuming and the high animal burden which has raised ethical concerns (Madia et al., 2016) . For these reasons, there is a demand for alternative strategies and methods in this area (Benigni, 2012) . The following paragraphs describe some of the initiatives undertaken to investigate possible alternative solutions.
In vitro test methods
In addition to the genotoxicity study package as described above, the in vitro cell transformation assays (CTAs) were shown to model some of the key stages of the in vivo carcinogenesis process, and have been in use for more than four decades to screen for potential carcinogenicity as well as investigate mechanisms of carcinogenicity (EURL ECVAM, 2013) . Validation studies and their peer-reviews were conducted to assess the CTA protocols standardisation, transferability and reproducibility (OECD, 2012d; OECD, 2014c) . They resulted into the adoption of two OECD Guidance Documents on the Syrian Hamster Cells (SHE) CTA (OECD, 2015d) and the Bhas CTA (OECD, 2016k). CTAs are faster and more cost efficient than the in vivo rodent carcinogenicity assay, providing a useful approach for screening of chemicals with respect to their carcinogenic potential. Although CTAs may help to decide, in conjunction with other available data and in a weight of evidence evaluation, whether a chemical possesses a carcinogenic potential (ECHA, 2017; Benigni, 2012) , the widespread adoption is prevented by a fundamental lack of understanding of the mechanistic basis of the morphological transformation observed in CTA assays and its relevance to the established Adverse Outcome Pathways involved in non-genotoxicity mediated carcinogenesis. For example, the cell transformation assays are restricted to the detection of effects of chemicals at the cellular level and will not be sensitive to carcinogenic activity mediated by effects exerted at the level of intact tissues or organisms (ECHA, 2017).
Waiving of the two-year carcinogenicity studies
The EPAA has sponsored a project aiming at the reduction in the use of animals for assessing the potential for carcinogenicity, whilst identifying opportunities for improving the science supporting the regulatory testing of medicines and chemicals. In this project, the University of Wageningen collaborated with the Dutch Medicines Evaluation Board to compile and analyse a database on active pharmaceutical ingredients. The aim was to confirm and expand previous investigations by Sistare et al. (2011) , and identify opportunities for waiving the two-years carcinogenicity studies based on in vitro genotoxicity testing and the results of (sub-)chronic toxicity studies. The study analysed 289 pharmaceutical compounds. In addition to the histopathological approach proposed by Sistare et al. (2011) , the pharmacological properties of the tested compounds were also taken into account (van der Laan et al., 2016) . When integrating the pharmacological properties of the compounds with respect to the presence or absence of a direct or indirect proliferative action, the results showed a prediction rate of 92% for non-carcinogens compounds and 98% for carcinogen compounds (van der Laan et al., 2016) . These data provide evidence that a waiver could be granted based upon existing knowledge gathered during the earlier development of the compound, and that a two-year carcinogenicity study in rats could be waived without compromising human safety.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is currently evaluating the possible revision of the rodent carcinogenicity testing of pharmaceuticals (ICH S1). The aim of such revision is to introduce a more comprehensive and integrated approach to address the risk of human carcinogenicity of small molecule pharmaceuticals, and to define conditions under which the two-year rat carcinogenicity studies add value to the assessment. This is based on the knowledge gained as described above, that pharmacologic targets and pathways together with toxicological and other data, may, in certain cases provide sufficient information to anticipate the outcome of the two-year rat carcinogenicity studies. A prospective evaluation period is foreseen within the ICH proposed revisions wherein carcinogenicity assessment documents will be collected and submitted to drug regulatory agencies in order to compare the proposed approach with the two-year rat carcinogenicity studies.
Integrated testing approaches for genotoxicity and carcinogenicity testing
The International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) addressed ways to advance the scientific basis for the interpretation of positive results of in vitro genetic toxicity assays, to facilitate the development of follow-up testing strategies and to define criteria for determining the relevance to human health . Specific needs were identified for improving testing, data interpretation and risk assessment. In particular, it was highlighted the willingness from various sectors to move from a hazard identification approach to a realistic risk-based approach (Boobis et al., 2016 ) that incorporates information on mechanism of action, kinetics and exposure Boobies et al., 2006; Meek et al., 2014) . As a follow-up action, ILSI-HESI proposed a decision process flow chart to be applied in case of clear positive results of in vitro genetic toxicity testing (Dearfield et al., 2011) . The proposed testing strategy provides a variety of different possibilities and allows flexibility in choosing follow-up action(s) depending on the results obtained in the initial battery of assays and on the available information. The intent was not to provide a prescriptive testing strategy, but rather to reinforce the concept of weighing the totality of the evidence (Dearfield et al., 2011) . Furthermore, ILSI-HESI addressed possible approaches to derive point of departure estimates, which can be used to derive reference doses and margin of exposure values that can be useful for the evaluation of human risk and for regulatory decision making (Johnson et al., 2014) .
The performance of an integrated approach to testing and assessment (IATA) designed to predict rodent genotoxic carcinogenicity covering different genotoxic mechanisms causing cancer has also been investigated by Petkov et al. (2016) . The IATA is docked to the OECD toolbox and uses measured data for different genotoxicity endpoints when available. Alternatively the system automatically provides predictions by SAR genotoxicity models. The study made use of the EU Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) genotoxicity and carcinogenicity consolidated database of Ames positive chemicals which compiles available genotoxicity and carcinogenicity data for 726 Ames positive chemicals originating from different sources as recommended within an EURL ECVAM workshop .
Finally, non-genotoxic carcinogens also contribute to an increased cancer risk by a variety of mechanisms that are not yet included in international regulatory approaches. To address this need, an integrated approach to testing and assessment (IATA) of non-genotoxic carcinogens is being developed (Jacobs et al., 2016) . The approaches for evaluating the carcinogenic potential of substances, including whether carcinogenicity studies should be conducted, can differ substantially across sectors (Madia et al., 2016 ). An expert working group has been set up under the auspices of the OECD to examine the current international regulatory requirements and their limitations in respect to non-genotoxic carcinogenicity, and how an IATA could be developed to assist regulators in their assessment of non-genotoxic carcinogenicity. Moreover, the working group is tasked to review, describe and assess relevant in vitro assays with the aim of tentatively organising them into levels of testing, following the adverse outcome pathway format, such as that possible structure(s) of the future IATA(s) can be created (Jacobs et al., 2016) .
Conclusions
The complexity of the carcinogenicity process makes it difficult to develop in vitro alternative test models that mimic the full process, especially for non-genotoxic chemicals. The challenge in developing in vitro alternatives is also heightened due to the complexity and number of target organs (EURL ECVAM, 2013) . The development of in vitro methods for carcinogenicity testing faces therefore a number of technical and scientific challenges, especially when evaluating the carcinogenicity of non-genotoxic chemicals or specific classes of compounds such as biologicals and nanomaterials (Madia et al., 2016) . However, strategies have been and are being proposed that integrate information derived from various sources, allowing to reduce the need for animal testing whenever possible Dearfield et al., 2011; Jacobs et al., 2016; Petkov et al., 2016; van der Laan et al., 2016) . Finally, attempts are made to move towards a risk-based approach that incorporates information on mechanism of action, kinetics and human exposure (Dearfield et al., 2011; Johnson et al., 2014) .
Applicability of alternative methods for vaccines
Vaccines represent a highly cost effective tool for preventing and controlling infectious diseases. Derived from biological sources, vaccines are relatively heterogeneious products, compared to traditional pharmaceutical and biopharmaceuticals and often have complex compositions. As such they are required to undergo quality, safety and potency (efficacy) control testing during development and in routine production, before being released in the market. Traditionally, laboratory animals and/or target species have played an important role in safety and/or in potency control testing of vaccines and still, many animals are used in Europe for this purpose (Halder, 2015) . However, ethical, scientific and economic reasons strongly call for the use of the 3Rs principle in vaccine development and production.
In particular, a number of efforts have been undertaken to develop 3R methods for the batch release testing of vaccines routine production. For example, progress has been made regarding the use of reduction alternatives by using e.g., single dilution testing and reducing the number of dose groups or animals per group. Furthermore, refinement alternatives such as the use of humane endpoints and/or serological methods replacing challenge procedures have been introduced. Finally, alternatives have been developed for the replacement of specific animal tests in batch release testing by non-animal alternatives such as cell based methods and/or immunochemical techniques. The efforts undertaken by vaccine manufacturers, academia and control authorities resulted, over the last decades, in a number of 3R methods being included into the European Pharmacopoeia (Ph. Eur.) (Milne and Buchheit, 2012) . The implementation of alternative methods in vaccine production is being further facilitated by the introduction of Good Manufacturing Practices, Quality-by-Design and the use of adequate and stringent quality control measures so that consistency based quality control measures (including non-animal tests) can be put in place without compromising the quality, safety and efficacy of vaccines during production.
In contrast, challenges still remain regarding human vaccines preclinical development which assesses among others the immunogenicity, potential impact on patient safety, local reactions and tolerance of vaccines. Although there is a willingness to move towards non-animal methods, the currently available non-animal models may not be mature enough to be able to fully mimic the complexity of the immune system. This chapter addresses the latest developments on 3R alternative approaches for vaccines testing with a main focus on their application for batch release testing and consistency approach. It also discusses the main challenges to be overcome in order to progress the implementation of 3Rs alternatives in human vaccines pre-clinical development.
Batch safety testing of vaccines
A number of efforts have been undertaken to eliminate animal testing or develop alternatives for batch safety testing of vaccines. Alternative cell based methods developed for commercial vaccines encompass for example testing absence of toxin and irreversibility of toxoid for diphteria vaccine, testing residual pertussis toxin and irreversibility of pertussis toxoid for acellular pertussis vaccines, testing specific toxicity for whole-cell pertussis vaccines, and neurovirulence testing for lot release of live polio vaccines (Halder, 2015; EURL ECVAM, 2016) . In 2015, the EPAA organized an international workshop on the harmonisation of 3Rs application in biologicals and its impact in achieving improved scientific reliability of the quality control (for safety and potency testing) of medicinal products (Schutte et al., 2017) . Regarding the safety testing of biologicals, it was recommended to actively encourage, at a global level, the deletion of the Abnormal Toxicity Tests (Ph. Eur. 2.6.9; EDQM, 2015a) and of the Target Animal Batch Safety Tests from all relevant legal requirements and guidance documents such as country-specific guidelines, pharmacopoeia monographs and WHO recommendations.
The Abnormal Toxicity Test (ATT), also referred to as General Safety Test (GST) or test for innocuity, is carried out in mice and/or guinea pigs and aims at detecting non-specific contaminants or toxins. This animal test was developed in the early 1900's to ensure the safe and consistent production of serum products, for example, to assess the preservative phenol level of diphtheria antiserum. It was later expanded to a general 'safety' test to detect extraneous contaminants (other than, for example, bacterial endotoxins) in biological products and has not significantly changed since around 1940. The scientific validity and rationale of the ATT, which was incorporated into most national or international pharmacopoeias and requirements, has been criticized for many years (Duchow et al., 1994) . Especially, after the introduction of Good Manufacturing Practices and, most importantly through the use of adequate and stringent quality control measures, the relevance of the ATT has become highly questionable. Consequently, the ATT has been deleted as a routine batch release test from more than 80 monographs of the European Pharmacopoeia (Schwanig et al., 1997) . Nowadays more adequate quality control measures (including non-animal tests) are in place, and the omission of ATTs does not compromise the safety of human vaccines or any other human pharmaceutical (Schutte et al., 2017) . For example, contaminants are controlled via a number of validated and specific tests that aim at detecting, e.g., microbiological contaminants or residual contaminants (Garbe et al., 2014) . Finally, in 2017, the European Pharmacopoeia Commission endorsed the complete deletion of the ATTs from the production section of the Ph. Eur. Furthermore, the general safety test (GST) requirements for biological products has been removed from the US 21 CFR Parts 601 and 680 in 2015. This is due to the fact that existing codified GST regulations were considered duplicative of requirements that are also specified in biologics license applications, or are no longer necessary or appropriate to help ensure the safety, purity, and potency of licensed biological products. Nevertheless, EU manufacturers working in accordance to the principles of the 3Rs may still face difficulties when producing for the global market, as ATT may still be required to satisfy recommendations from the World Health Organization (WHO), from the World Organization for Animal Health (OIE) and/or from specific national regulatory requirements such as China, Japan and Russia (Schutte et al., 2017) . Due to the lack of scientific relevance of the ATTs, it was recommended that the test be deleted, at a global level, from national or international pharmacopoeias (Garbe et al., 2014; Schutte et al., 2017) .
The Target Animal Batch Safety Tests (TABST) on the other hand, is a routine quality control test used to demonstrate that a veterinary vaccine batch is safe in the target animal. Since 2004 in Europe, performance of the TABST for each batch of veterinary vaccine may be waived upon provision of consistency data for at least 10 batches. Subsequently, in 2012, the TABST was deleted from the Ph. Eur. monographs for all veterinary vaccines with two specific, scientifically justified exceptions and renaming of the test to 'residual toxicity test' to avoid misunderstandings (EDQM, 2013; Schutte et al., 2017) . However, the TABST is still required in non-EU countries such as Brazil, China, India, South Korea, Taiwan and Russia. Of these, some countries may allow specific waivers, while others do not (Schutte et al., 2017) . The Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) has made progress towards harmonizing criteria for waiving the TABST, and it has published the VICH guideline GL50 for inactivated vaccines. However, this VICH guideline GL50 still required data on at least 10 consecutive batches and product-specific variations prior to removal of the test (VICH, 2013) . Participants from the EPAA workshop agreed that there was a lack of scientific evidence demonstrating that the TABST contributes to the safety of veterinary vaccines, as well as a lack of scientific basis for the '10 batches' waiving approach, and that the main barrier to deletion of TABST appears to be local legal requirements (Schutte et al., 2017) . Following these recommendations, discussions were initiated at both WHO and OIE level regarding the deletion of TABST (Schutte et al., 2017) . More recently, a second VICH guideline GL55 for live vaccines and a revised version for GL50(R) have been published in 2017 to be implemented in 2018 (VICH 2017a,b) . Requirements have been slightly changed and both guidelines require data on 10 batches, or a minimum of 5 batches if 10 batches are not manufactured within 3 years. Moreover, a guideline on waiving criteria for the abnormal toxicity test for veterinary vaccines is under development.
Batch potency testing of vaccines
Potency testing of vaccines aims to demonstrate with a suitable method that a given vaccine lot induces a protective immune response comparable to that shown to be efficacious in humans or target species. Depending on the type of vaccine, this may involve animal tests, e.g. immunisation-challenge or immunisation-serology assays for some inactivated vaccines, or may be carried out in vitro (antigen quantification assays for live vaccines or well-defined inactivated vaccines) (Halder, 2015) . Immunisation-serology assays are more humane animal-based models for measuring potency, where animals are immunised and after a certain period the antibody levels induced by the vaccine are measured with an immunochemical in vitro method (Halder, 2015) . Reduction and refinement alternatives have been implemented in the Ph. Eur. for well-established vaccines. In addition, a number of initiatives are currently taking place in order to investigate the use of physico-and immunochemical techniques to characterize antigens and to apply them for the vaccine quality control as described below.
Regarding the human rabies vaccines, the EPAA supports a project aiming at replacing the current in vivo potency test (NIH, mice intracranial challenge test) with an in vitro antigen (G glycoprotein) quantification assay based on ELISA technology. The NIH test involves large numbers of animals, half of which develop rabies. Furthermore, the NIH test is highly variable and the test may have to be repeated to meet regulatory requirements. Based on a pre-collaborative study, a candidate ELISA replacement method has been identified. It is undergoing validation for transferability and robustness through a wide collaborative study. The study is run under the Biological Standardisation Programme of the Council of Europe and the EU Commission, coordinated by the European Directorate for the Quality of Medicines (EDQM, study coded BSP148). Furthermore, an EPAA project for the validation of an alternative method for the control of the potency of veterinary rabies vaccines has been incorporated into the IMI2 VAC2VAC project (see below under consistency approach).
Finally, to facilitate the global regulatory acceptance of non-animal methods for the potency testing of vaccines (e.g., for human diphtheria and tetanus vaccines and veterinary swine erysipelas vaccines), international convergence on the scientific principles of the use of appropriately validated in vitro assays for replacing in vivo methods was identified as an overarching goal during the 2015 EPAA workshop (Schutte et al., 2017) . The establishment of scientific requirements for new assays was recognized as a means to unify regulatory approaches in different jurisdictions. Furthermore, it was recommended to include key regulators and manufacturers early in the discussions, and that manufacturers and responsible expert groups, e.g. at the EDQM and Health Care of the Council of Europe or the European Medicines Agency consider taking the leadership for international collaboration (Schutte et al., 2017) .
The consistency approach
Recent developments in vaccine processes include the implementation of Good Manufacturing Practices, Quality-by-Design and/ or in-process controls. These developments allow, as compared to previously used processes, for a better characterization of the product, an improved optimisation and standardisation of the production process, a tight in-process control, and the use of quality systems to ensure consistency of vaccine quality. By doing so, it is possible to assess the quality of vaccine batches by demonstrating the similarity of their profile with a reference vaccine of proven clinical safety and efficacy, which is referred to as 'the consistency approach'. This approach is encouraged, together with the use of 3Rs methods, by the Ph. Eur. (EDQM, 2015b) . The use of consistency approach for batch release offers a means of implementing 3Rs which is part of an integrated approach and makes use of progress in process technologies. There is agreement on that the consistency approach is key in promoting the regulatory acceptance of new assays (Schutte et al., 2017) .
To ensure adequate control, the new methodologies have to capture the key quality attributes that are essential to maintain the safety and efficacy of the product established at the time of licensure (Schutte et al., 2017) . Some elements for consistency testing include: structural/ physicochemical analyses, functional in vitro testing (e.g. monocytes cocultures, etc), binding immunochemical assays (e.g., Mab ELISA's, biosensor analysis, electrophoresis, etc) and molecular biology (e.g., microarrays, transcriptomics, proteomics). With the consistency approach, the quality is linked to well characterised clinical/historical batch (scientific benefit), the quality control testing is faster representing a few days instead of couple of months (patient benefit), and no further animal use is required (animal welfare benefit).
Efforts to implement the consistency approach are supported by industry, government and research (Metz et al., 2007; Hendriksen et al., 2008; De Mattia et al., 2011; Halder, 2015) . In particular, EURL ECVAM and EPAA organized a workshop in 2010 (De Mattia et al., 2011) and, as a follow-up, EPAA launched in 2011 a project on the application of the 3Rs and the consistency approach for improved human and veterinary vaccine quality control. A series of meetings and workshops on four vaccines identified as priority (i.e., diphtheria, tetanus and acellular pertussis vaccines; human rabies vaccines; veterinary rabies vaccines and clostridial vaccines) were held to discuss the consistency approach and its implementation in more detail with experts from regulatory bodies, manufacturers and academia (De Mattia et al., 2015) . Furthermore, the Ph. Eur. adopted in 2016 the new general chapter 5.2.14 on the "Substitution of in vivo method(s) by in vitro method(s) for the quality control of vaccines". The new chapter provides guidelines on validation of substitute methods where a direct head-to-head comparison with an existing in vivo method is not possible. It deals with potency tests, safety tests and specific toxicity assays, and states that in vitro methods need to reflect both antigen content and functionality.
However, a number of barriers have also been identified for the implementation of the 3Rs in the consistency approach by the participants of a workshop comprising industry, regulators and scientific institutes (Bruysters et al., 2017) . The main barriers identified comprised 1) the conciliation of industry and regulators expectations regarding e.g. the submission of marketing authorisation, 2) the international harmonisation in the acceptance of alternative approaches, 3) the economical implications related to the transition from the current procedures (whose underlying mechanisms are largely unknown) to the comprehensive knowledge of the entire production process and the critical quality parameters and 4) the scientific needs to exchange the information gained to all stakeholders, and in particular the absence of 'real' failed batches, identified as a major obstacle, where most studies make use of artificially degraded batches (Bruysters et al., 2017) .
The lack of predictive value of the animal models was recognized and provides an incentive to move to alternative assays. However, results obtained from in vitro tests are often difficult to link to those obtained in vivo, or to the human situation. In particular, it was regarded difficult to mimic in vivo immune responses to all vaccine antigens/ epitopes by in vitro assays, and to investigate adjuvanted vaccines in vitro. Furthermore, most animal tests are performed on vaccine products that have been introduced long ago, implicating limited production characterization and a lack of knowledge on critical product characteristics and correlates of protection. Finally, the unfamiliarity between all stakeholder groups was also considered a barrier for the implementation of the consistency approach (Bruysters et al., 2017) .
One opportunity to overcome these barriers is the Innovative Medicine Initiative 2 (IMI-2) recently funded project "Vaccine batch to vaccine batch comparison by consistency testing" (VAC2VAC; http:// www.vac2vac.eu/). The project initiated in 2016 and comprises 21 partners from both public entities and industry. It aims to develop and validate quality testing approaches and establish the concept of the consistency approach for quality control of established human and veterinary vaccines using non-animal methods, where current quality control approaches are still relying on in vivo methods.
Conclusions
The traditional in vivo tests required for vaccine testing have been established before the current licensing procedures for biologicals had been implemented. If in the past, vaccine production has been based on a risk based approach, in the recent years vaccines benefit from better production process, better in-process controls and better analytical methods. Furthermore, many in vivo methods only allow 'pass-fail' assessments, whereas, in vitro assays that use advanced analytical methods potentially enable more reproducible qualitative and quantitative product assessments. In selecting the best test method(s) for a given purpose, the best science should prevail and application of appropriately validated non-animal methods should ensure the supply of biologicals of acceptable quality (Schutte et al., 2017) .
A number of achievements were made in implementing 3Rs alternatives for the quality control of vaccines as described above, and as the use of Vero cell-based assay for the assessment of residual diphtheria toxin and irreversibility of toxoid at drug substance stage, or the use of Chinese hamster ovary (CHO) based assays for the assessment of residual pertussis toxin and irreversibility of toxoid at drug substance stage. However, there is still room for improvement, such as the need for development of alternative methods at the drug substance stage (in solution) and/or drug product stage (with adjuvant) in order to allow for the replacement of current in vivo potency assays for diphtheria, tetanus and pertussis vaccines. The need for further research is highlighted by the approval of the IMI2 VAC2VAC project, in which the consistency approach offers an opportunity to overcome some of these barriers.
Furthermore, if measurable progress has been made on the use of alternatives to animal testing for vaccine batch release, additional efforts are still needed in order to achieve full replacement of animal testing for the development of new vaccines before it enters first in man. Some technologies are progressing such as organs-on-a-chip but there are still a number of scientific challenges to be addressed before uncovering the scientific complexity of the full immunologic process and taking into consideration the added complexity of the adjuvant system used in vaccines. Some of the current scientific challenges include the fact that 1) functional epitopes are not yet well characterised, 2) there may be adjuvant antigen interaction, 3) the cross-reaction of antigens in vivo in combined vaccines cannot be evaluated in vitro, 4) multiple epitopes may be related to protection and 5) the mode of action of vaccines is not yet fully characterised.
Finally, improving the international recognition of assays and building the regulatory authorities' confidence in the new methods is key in promoting their global acceptance. In striving for international acceptance of a specific assay or an overarching testing strategy (including the deletion of no longer relevant tests), it is imperative to ensure that all relevant regulators are involved (Schutte et al., 2017) .
Risk assessment
A key part of a risk assessment are considerations of exposure and dose-response, in addition to the evaluation of hazard. An appropriate risk assessment based on e.g. in vitro data entails considering information to establish the relevance to human situations such as exposure assessment and physiologically based pharmacokinetic (PBPK) modelling in addition to the identification and characterization of hazard such as adverse-outcome pathways, dose-response and potency. Leonard et al., 2016 for example, reported on an integrated approach considering in vitro data, pharmacokinetic properties and exposure levels, predicted through high-throughput means, for interpreting adverse outcome pathways based on biological responses, and ultimately estimated the margin of exposure to thyroid peroxidase inhibitors. The authors conclude that evaluation of hazard or external exposure alone when prioritizing chemicals for risk assessment may be insufficient and that consideration of pharmacokinetic properties is warranted. Dent et al. (2015) on the other hand reviewed the in vitro tools, pharmacokinetics and adverse outcome pathway approaches that may be used to develop a non-animal safety assessment and provide a pathway-based safety assessment for anti-androgenic effects in humans. The authors concluded that, especially for chemicals with low anti-androgenic activity, human exposure data can be useful to place in vitro mode of action data into context for risk-based safety decision-making.
Evaluation of exposure is a key element within risk assessment. The extent of required toxicity testing will depend on the qualitative and quantitative aspects of the exposure estimates. The science of exposure assessment represents a developing field due to the increasing needs for exposure data for individuals and populations. The current in silico and in vitro models available are in general crude and useful for the first tier of safety and exposure assessment. For higher tiers of risk assessment, that need more realistic estimates of exposure to e.g. consumers, in silico and in vitro models are developing and improving. For example, probabilistic approaches that take into account frequency of use and probability of exposure scenarios allow to model the use of single products and yield aggregate exposure values that are more realistic than values obtained through deterministic approaches. Nijkamp et al., 2015 provide for example a quantitative risk assessment for the sensitising fragrance geraniol based on an aggregate dermal exposure to geraniol, estimated using probabilistic aggregate consumer exposure model. However, some limitations still exist related to i) data gaps for specific populations (e.g., outside EU and US, children/babies, pregnant woman, etc.), ii) the need for structured methodologies for exposure data assessment and their integration in risk assessment, and iii) the regulatory acceptance of probabilistic assessment of aggregate exposure to chemicals.
In order to achieve a full risk assessment based on non-animal methods, it will be key to ensure the availability of non-animal tools covering the watershed of toxicity pathways and filling the current knowledge gaps which prevent their use in e.g. predicting the type and severity of in vivo effect(s) that could arise from a given level of in vitro outcome (Dent et al., 2015) . In addition, further work would be useful to refine the human systemic exposure estimates including addressing uncertainties in plasma protein binding, liver metabolism and renal clearance (OECD, 2017f) . Similarly, it will be necessary to characterize the in vitro exposure scenario to enable comparison to the human systemic exposure, and ultimately convert the in vitro concentration to the doses relevant to humans (OECD, 2017f) . Further advances in these areas will require increased research, evaluation of reliability, relevance and reproducibility, improved collaboration between stakeholders and regulatory acceptance of the new methodologies.
Discussion and conclusions
As described in the previous paragraphs, the main forces driving the use of alternative methods to animal testing include regulatory requirements, scientific advances and ethics. A number of regulations such as for cosmetics products and ingredients (EC, 2009a) , for the testing of industrial chemicals (EC, 2006) , mixtures (EC, 2008) , biocides (EC, 2012), plant protection products (EC, 2009b) and pharmaceuticals (EMA, 2016a (EMA, , 2016b call for the use of alternative methods to animal testing in the EU (EC, 2010a). This is reflected by the increasing number of official Test Guidelines, Guidance Documents and monographs on alternative methods that have been adopted at the OECD level and by the European Pharmacopoeia during the last decade. Besides the ethical concerns raised and the suffering animals may endeavour (e.g. vaccines testing), and/or the high number of animals needed (e.g. carcinogenicity and vaccines), there are also scientific concerns regarding the human predictivity (e.g., carcinogenicity, vaccines) and reproducibility of animal testing (e.g. Draize rabbit eye test, NIH test for rabies vaccines). Finally, it is considered that some in vivo methods may only allow 'pass-fail' assessments, whereas in vitro assays can, at least in some areas such as vaccines quality testing, enable more reproducible qualitative and quantitative assessments.
For these reasons there is a strong willingness to move from standard animal studies towards more scientifically tailored human relevant approaches making use of e.g. integrated approaches and safety assessment strategies that combine information sources coming from multiple origin such as physico-chemical properties, in silico test methods in weight-of-evidence approaches with the integration of toxicokinetics, ADME, PBPK and QIVIVE considerations. In addition, there is progress towards reducing and refining the use of animals. For example, animal methods that are no longer scientifically relevant have been deleted in some areas such as acute toxicity and vaccines (e.g. ATT, TABST). Furthermore, waiving of animal testing is proposed for e.g. carcinogenicity testing of pharmaceutical products, based on considerations of existing information such as pharmacological properties and chronic animal studies. Finally, refined and alternative approaches are proposed to be used in order to select the higher tested doses (e.g. repeated dose toxicity) and/or to derive the point of departure estimates to derive reference doses and mode of exposure values that can be useful for evaluating human risk (e.g. carcinogenicity).
However, a number of scientific and technical challenges still exist in order to ensure a broader implementation of alternatives to animal testing. These can be identified as the following needs: i) to further characterize the pathways of toxicity and how they interact; ii) to develop new alternative methods for the pathways of toxicity where gaps still exist, iii) to better characterize the link between in vitro outcome and the severity of effects occurring in the target species; iv) to better characterize the applicability and limitations of the available alternative methods in absence of formal validation programmes, and v) to ensure the appropriate implementation of the available tools/safety assessment approaches. In addition, for those areas where accepted alternative methods are available (e.g., vaccines), the harmonised acceptance by competent authorities across different geographical regions was pointed as another important factor in order to ensure the broader application of alternative approaches.
The alternative methods currently available do not always allow coverage of all mechanisms and pathways of adverse effects occurring in the target species. For example, for more complex endpoints such as repeated dose toxicity and carcinogenicity, the in vitro models currently available are not able yet to mimic all possible interactions, the effects exerted at the level of intact tissues and/or organs and the full complex kinetics and biotransformation processes which may occur in the target species. There is a need for improved biokinetic models which correctly estimate the impact of the distribution over time, the repeated external exposure and resulting internal dose. Furthermore, there is a need for quantitative in vitro to in vivo extrapolation (QIVIVE), toxicokinetics and understanding of dose-response. Similarly for vaccines, there is a need for new models that are able to mimic the complexity of immune responses to the vaccine antigens/epitopes, which allow investigating adjuvanted vaccines (e.g. adjuvant-antigen potential interactions), and assessing possible cross reaction of antigens occurring in vivo, for example in combined vaccines.
In order to develop new tools that can cover the existing scientific gaps as described above, there is the need to better understand the mechanisms of action, key events of the adverse outcome pathways in systemic toxicity following acute or chronic exposure. Similarly, there is a need to better understand the mechanisms of action and further characterize the functional epitopes of relevance for vaccine testing.
For the more complex endpoints, there is a need to link the levels of in vitro outcome to the severity of effects occurring in vivo. For example, it is necessary to understand to what extent early gene changes can contribute to the expression of biomarkers of toxicity. Deriving safety values from in vitro data for repeated dose toxicity is one of the biggest challenges. There is a need to develop tools that allow integrating biotransformation and ADME, so that in vitro outcomes can be applied for quantitative risk assessment. Similarly, there is a need to characterize the in vitro exposure scenario to enable comparison to the systemic exposure, and ultimately convert the in vitro concentration to the doses relevant to the target species. Finally, there is a need to develop structured methodologies for exposure assessment by demographics (e.g. race, gender, age, etc.) and to refine human systemic exposure estimates including uncertainties in e.g. plasma protein binding, liver metabolism and renal clearance.
When implementing the available alternative approaches, it is important to take into account their applicability and limitations regarding e.g., chemical classes and physical-chemical characteristics (e.g. solubility). In particular, it could be useful to better characterize the association between toxic pathways and chemical properties. Furthermore, it is important to ensure the appropriate implementation and use of the most predictive methods available. Indeed, some regulatory test methods may lead to a high number of false positives, such as for genotoxicity testing or the use of additivity approach for the eye hazard assessment of detergents. When making use of read-across approaches in contrast, it is important to ensure the quality of data for the source chemical, as well as to clearly justify similarity i.e. not only taking into account the chemical structure but also other elements such as toxicokinetic and/or toxicodynamic properties. Economic implications may also hamper in some cases the broader implementation of alternative methods, such as for the consistency approach for vaccines.
Finally, the regulatory acceptance of alternative methods currently available may differ across different geographical regions, which for a global industry can hamper the large scale implementation of such methods. For example, there can be differences in the adoption of UN GHS (sub-)categories for skin irritation and corrosion across regions and/or regulatory agencies. Furthermore, the acceptance of weight-ofevidence approaches and/or defined approaches may be considered on a case-by-case basis. The unfamiliarity of stakeholder groups to the new approaches may be a possible reason for the differences in acceptance of alternative approaches. It is therefore critical that all relevant stakeholders are involved to ensure international acceptance of a specific assay or overarching testing strategy. Building regulatory authorities' confidence in new methods is key for promoting their global acceptance. Furthermore, the establishment of scientific requirements and international convergence on the scientific principles of use of appropriate alternative methods is considered important in order to favour the harmonised implementation of 3Rs alternatives.
In conclusion, overall the main constraints to the application of nonanimal alternatives are the still existing gaps in scientific knowledge and technological limitations. There is a large acceptance of the need to move from hazard identification approaches to a more comprehensive risk-based approach that incorporates information on exposure, kinetics and mode of action. It is believed that the best science should prevail in selecting the most appropriate test method(s) for a specific purpose such as e.g., the use of the consistency approach proposed for the testing of vaccines, which allow a thorough characterization of the product and of the process. Scientific robustness is considered key in ensuring the regulatory acceptance of new assays.
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